Infinite Epigenetics acquires Tally Health in ‘largest epigenetic testing deal to date’

Infinite Epigenetics has acquired Tally Health, combining their epigenetic testing and analytics capabilities with Tally Health’s consumer-facing longevity brand and supplement offerings. The deal brings together the largest private DNA methylation dataset, enabling enhanced validation of interventions like nutrition and supplements across broader populations. Tally Health will continue as a standalone brand while gaining access to Infinite Epigenetics’ laboratory infrastructure and expanded datasets, supporting more data-driven product development and iterative formulation. Both companies will use the combined platform to link epigenetic testing data with downstream interventions and continuously evaluate their impact on biological aging.